12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vytorin ezetimibe/simvastatin: Phase III ongoing

An independent DSMB recommended continuation of the double-blind Phase III IMPROVE-IT trial comparing Vytorin vs. Zocor simvastatin in 18,141 patients. IMPROVE-IT, which has completed enrollment, is slated to complete in September 2014 with 5,250 pre-specified primary endpoint events. Last year, an independent DSMB recommended continuation of IMPROVE-IT after it...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >